Sedana Medical AB (FRA:7D2A)

Q2 2025 Sedana Medical AB (publ) Earnings Call Transcript

Jul 18, 2025 / 11:30 AM GMT

Release Date Price: €1.1 (+4.74%)

Transcript

Key Points

Positve

Sedana Medical AB (OSTO:SEDANA) achieved record sales in Q2 2025, with a year-over-year growth of 27%, driven by strong performance in Germany and organic growth.
The company received positive clinical trial results in the US, including FDA fast track designations and approval for an early access program.
The pediatric study results were published in The Lancet, leading to approval for use in children in 13 countries and extended data exclusivity.
Sedana Medical AB (OSTO:SEDANA) reported a positive EBITDA year-to-date, with significant improvements in profitability and cost management.
The company is on track to achieve its financial targets for the year, with a strong outlook for the second half due to the impact of a newly acquired manufacturing plant on gross margins.

Negative

Growth in other direct markets, such as France and the UK, was slower than expected due to execution issues and specific customer circumstances.
The company experienced a temporary sales decline in the UK due to halted deliveries and personnel changes at customer sites.
Cash flow from operations was negative, driven by changes in working capital and US CapEx related to NDA submission preparations.
The distributor market showed irregular order patterns, leading to fluctuations in sales performance.
Despite positive trends, the company faces challenges in switching customers from sevoflurane to isoflurane in France, impacting overall growth in that market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SEDANA.ST - Sedana Medical AB (publ)
Q2 2025 Sedana Medical AB (publ) Earnings Call
Jul 18, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello everyone. Welcome to today's presentation with the Sedona Medical. With us presenting today, we have the CEO Johannesta, CFO Joan Spetz, and CMO Peter Sakki.

We'll do a Q&A of the presentation, and if you're calling in, I would like to ask a question, please press 9 to raise your hand and 6 on mute yourself when you get the word. You can also type in the messages informed to the right.

And with that said, please go ahead with your presentation.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you for the introduction and welcome to our

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.